{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}],"title":"No"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion, the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210, molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study, the control gene was abl.","groups":[{"description":"1 year to \\< 10 years pediatric patients","id":"OG000","title":"Group 1"},{"description":"\\>= 10 years to \\<18 years pediatric patients","id":"OG001","title":"Group 2"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.","reportingStatus":"POSTED","timeFrame":"minimum of 12 cycles (28 days per cycle)","title":"Number of Ph+ CML Participants With Major Molecular Response (MMR)","type":"SECONDARY","unitOfMeasure":"Participants"}